Skip to main content
TipRanks
Go Ultimate75% OFF

BioNxt Solutions (BNXTF) AI Stock Analysis

32 Followers
BNXTF

BioNxt Solutions

(Other OTC:BNXTF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Drug-delivery platform focusA defined focus on transdermal and oral thin-film drug delivery gives BioNxt a coherent development platform rather than a broadly diversified research agenda. If candidates advance, this specialization could support repeatable product development and create value from its related intellectual property.
Negative Factors
Revenue has collapsedRevenue has effectively disappeared after a sharp multi-year decline, leaving the company without a meaningful operating base to absorb research and corporate costs. Until product candidates generate commercial revenue, the business remains highly dependent on financing and vulnerable to prolonged operating losses.

BioNxt Solutions (BNXTF) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%BNXTF-62.80%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$22.82M
Dividend Yield
―
Average Volume (3M)
6,103
Price to Earnings (P/E)
-3.2
Beta (1Y)
1.20
Revenue Growth
―
EPS Growth
―
Country
US
Employees
25
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

BioNxt Solutions Business Overview & Revenue Model

Company Description

Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, incl...

BioNxt Solutions Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BNXTF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS57NeutralCAD 27.77M-9.23-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:AVCNTSE:AVCN48NeutralCAD 12.09M-4.09-65.40%―-3.32%-34.15%
TSE:INNOTSE:INNO45NeutralCAD 7.42M-5.56-19.37%―-19.20%42.54%
TSE:ATLETSE:ATLE42NeutralCAD 46.62M-0.76-2099.75%―-96.13%88.13%

* Healthcare Sector Average

Performance Comparison

-50%0%50%BNXTFTSE:ATLETSE:LABSTSE:AVCNTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BNXTF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BNXTFBionxt Solutions Inc0.19-0.27-59.21%
TSE:ATLEWillow Biosciences0.10-0.04-28.57%
TSE:LABSMedipharm Labs (Otc)0.070.000.00%
TSE:AVCNAvicanna Inc0.09-0.17-65.38%
TSE:INNOInnocan Pharma Corporation1.65-13.74-89.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.